|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 2121 K Street, NW, Suite 325 |
Address2 |
|
City | Washington |
State | DC |
Zip Code | 20037 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 1967-12
|
||||||||
|
6. House ID# 317210000
|
TYPE OF REPORT | 8. Year | 2018 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Lupe Gonzales Jr |
Date | 5/17/2019 3:12:08 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ALC
16. Specific lobbying issues
H.R.6-Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act
H.R.1057-Synthetics Trafficking and Overdose Prevention Act of 2017
H.R.1492-Medical Controlled Substances Transportation Act of 2017
H.R.2851-Stop the Importation and Trafficking of Synthetic Analogues (SITSA) Act of 2017
H.R.3545-Overdose Prevention and Patient Safety (OPPS) Act
H.R.4922-Stopping Overdoses of Fentanyl Analogues Act
H.R.5176-Preventing Overdoses While in Emergency Rooms Act of 2018
H.R.5197-Alternatives to Opioids (ALTO) in the Emergency Department Act
H.R.5531-Opioid Emergency Response Act
H.R.5558-Alternatives to Opioids Prescribing Act
H.R.6082-Overdose Prevention and Patient Safety (OPPS) Act
S.372-Synthetics Trafficking and Overdose Prevention Act of 2017
S.1327-Stop the Importation and Trafficking of Synthetic Analogues (SITSA) Act of 2017
S.1553-Stopping Overdoses of Fentanyl Analogues Act
S.2516-Alternatives to Opioids (ALTO) in the Emergency Department Act
S.2609-Recovery Coaches Offer Addiction Counseling and Healing (COACH) Act
S.2610-Preventing Overdoses While in Emergency Departments Act of 2018
S.2680-Opioid Crisis Response Act of 2018
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Wooster |
|
Associate Executive Director, Public Affairs |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Ryan |
McBride |
|
Senior Congressional Lobbyist |
|
Jeanne |
Slade |
|
Director, NEMPAC & ACEP Grassroots Advocacy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
H.R.880-Military Injury Surgical Systems Integrated Operationally Nationwide to Achieve ZERO Preventable Deaths Act
S.1022-Military Injury Surgical Systems Integrated Operationally Nationwide to Achieve ZERO Preventable Deaths Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Wooster |
|
Associate Executive Director, Public Affairs |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Ryan |
McBride |
|
Senior Congressional Lobbyist |
|
Jeanne |
Slade |
|
Director, NEMPAC & ACEP Grassroots Advocacy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DIS
16. Specific lobbying issues
Essential emergency medication shortages
H.R.880-Military Injury Surgical Systems Integrated Operationally Nationwide to Achieve ZERO Preventable Deaths Act
H.R.1822-Good Samaritan Health Professionals Act of 2017
H.R.1876-Good Samaritan Health Professionals Act of 2017
H.R.6378-Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
S.781-Good Samaritan Health Professionals Act of 2017
S.1022- Military Injury Surgical Systems Integrated Operationally Nationwide to Achieve ZERO Preventable Deaths Act
S.2852-Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Wooster |
|
Associate Executive Director, Public Affairs |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Ryan |
McBride |
|
Senior Congressional Lobbyist |
|
Jeanne |
Slade |
|
Director, NEMPAC & ACEP Grassroots Advocacy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code EDU
16. Specific lobbying issues
H.R.5734-Resident Education Deferred Interest Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Wooster |
|
Associate Executive Director, Public Affairs |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Ryan |
McBride |
|
Senior Congressional Lobbyist |
|
Jeanne |
Slade |
|
Director, NEMPAC & ACEP Grassroots Advocacy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FIR
16. Specific lobbying issues
H.R.3999-To amend title 18, United States Code, to prohibit the manufacture, possession, or transfer of any part or combination of parts that is designed and functions to increase the rate of fire of a semiautomatic rifle but does not convert the semiautomatic rifle into a machinegun, and for other purposes.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Wooster |
|
Associate Executive Director, Public Affairs |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Ryan |
McBride |
|
Senior Congressional Lobbyist |
|
Jeanne |
Slade |
|
Director, NEMPAC & ACEP Grassroots Advocacy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Essential emergency medication shortages
Mental health services for emergency psychiatric patients
Price transparency, out-of-network reimbursement of emergency medical services
H.Res.906-Congratulating the American College of Emergency Physicians on its 50th anniversary
H.R.6-Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act
H.R.372-Competetive Health Insurance Reform Act of 2017
H.R.548-Health Care Safety Net Enhancement Act of 2017
H.R.767-Stop, Observe, Ask, and Respond (SOAR) to Health and Wellness Act of 2017
H.R.817-End Surprise Billing Act of 2017
H.R.880-Military Injury Surgical Systems Integrated Operationally Nationwide to Achieve ZERO Preventable Deaths Act
H.R.1057-Synthetics Trafficking and Overdose Prevention Act of 2017
H.R.1215-Protecting Access to Care Act of 2017
H.R.1323-Reducing Unnecessary Emergency Room Visits under Medicaid Act
H.R.1492-Medical Controlled Substances Transportation Act of 2017
H.R.1565-Saving Lives, Saving Costs Act
H.R.1822-Good Samaritan Health Professionals Act of 2017
H.R.1876-Good Samaritan Health Professionals Act of 2017
H.R.2200-Frederick Douglass Trafficking Victims Prevention and Protection Reauthorization Act of 2017
H.R.2410-Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017
H.R.2851-Stop the Importation and Trafficking of Synthetic Analogues (SITSA) Act of 2017
H.R.2957-Save Rural Hospitals Act
H.R.3181-Medicare Choices Empowerment and Protection Act
H.R.3258-Marketplace Certainty Act
H.R.3545-Overdose Prevention and Patient Safety (OPPS) Act
H.R.4922-Stopping Overdoses of Fentanyl Analogues Act
H.R.5176-Preventing Overdoses While in Emergency Rooms Act of 2018
H.R.5197-Alternatives to Opioids (ALTO) in the Emergency Department Act
H.R.5531-Opioid Emergency Response Act
H.R.5558-Alternatives to Opioids Prescribing Act
H.R.5678-Rural Emergency Medical Center Act of 2018
H.R.5734-Resident Education Deferred Interest Act
H.R.6082-Overdose Prevention and Patient Safety (OPPS) Act
H.R.6143-Patient Right to Know Drug Prices Act
H.R.6144-Know the Lowest Price Act of 2018
H.R.6372-To require the Secretary of Health and Human Services issue regulations to ensure due process rights for physicians furnishing emergency medical services
H.R.6502-Reducing Unnecessary Senior Hospitalizations Act of 2018
H.R.6615-Traumatic Brain Injury Program Reauthorization Act of 2018
H.R.6733-Know the Cost Act of 2018
H.R.6748-Emergency Medical Services for Children Program Reauthorization Act of 2018
H.R.7223-Right Rebate Act of 2018
Senate resolution congratulating the American College of Emergency Physicians on its 50th anniversary
S.191-Patient Freedom Act of 2017
S.256-SOAR to Health and Wellness Act of 2017
S.284-End Surprise Billing Act of 2017
S.372- Synthetics Trafficking and Overdose Prevention Act of 2017
S.527-Health Care Safety Net Enhancement Act of 2017
S.568-Improving Access to Medicare Coverage Act of 2017
S.781-Good Samaritan Health Professionals Act of 2017
S.1016-Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2017
S.1022-Military Injury Surgical Systems Integrated Operationally Nationwide to Achieve ZERO Preventable Deaths Act
S.1130-Rural Emergency Acute Care Hospital (REACH) Act
S.1462-Marketplace Certainty Act
S.1530- Medicare Choices Empowerment and Protection Act
S.1553-Stopping Overdoses of Fentanyl Analogues Act
S.1835-Lower Premiums Through Reinsurance Act of 2017
S.2465-Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2018
S.2516-Alternatives to Opioids (ALTO) in the Emergency Department Act
S.2544-Patient Right to Know Drug Prices Act
S.2553-Know the Lowest Price Act of 2018
S.2609-Recovery Coaches Offer Addiction Counseling and Healing (COACH) Act
S.2610-Preventing Overdoses While in Emergency Departments Act of 2018
S.2680-Opioid Crisis Response Act of 2018
S.3482-Emergency Medical Services for Children Program Reauthorization Act of 2018
S.3531-Emergency Care Improvement Act
S.3657-Traumatic Brain Injury Program Reauthorization Act of 2018
S.3702-Right Rebate Act of 2018
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Wooster |
|
Associate Executive Director, Public Affairs |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Ryan |
McBride |
|
Senior Congressional Lobbyist |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
H.R.372-Competetive Health Insurance Reform Act of 2017
H.R.817-End Surprise Billing Act of 2017
H.R.1628-American Health Care Act of 2017
H.R.3258-Marketplace Certainty Act
H.R.6143-Patient Right to Know Drug Prices Act
H.R.6144-Know the Lowest Price Act of 2018
H.R.6733-Know the Cost Act of 2018
S.191-Patient Freedom Act of 2017
S.1462-Marketplace Certainty Act
S.1835-Lower Premiums Through Reinsurance Act of 2017
S.2544-Patient Right to Know Drug Prices Act
S.2553-Know the Lowest Price Act of 2018
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Wooster |
|
Associate Executive Director, Public Affairs |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Ryan |
McBride |
|
Senior Congressional Lobbyist |
|
Jeanne |
Slade |
|
Director, NEMPAC & ACEP Grassroots Advocacy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LAW
16. Specific lobbying issues
H.R.767-Stop, Observe, Ask, and Respond (SOAR) to Health and Wellness Act of 2017
H.R.1057-Synthetics Trafficking and Overdose Prevention Act of 2017
H.R.1492-Medical Controlled Substances Transportation Act of 2017
H.R.2200-Frederick Douglass Trafficking Victims Prevention and Protection Reauthorization Act of 2017
H.R.2851-Stop the Importation and Trafficking of Synthetic Analogues (SITSA) Act of 2017
H.R.4922-Stopping Overdoses of Fentanyl Analogues Act
S.372-Synthetics Trafficking and Overdose Prevention Act of 2017
S.256-SOAR to Health and Wellness Act of 2017
S.1327-Stop the Importation and Trafficking of Synthetic Analogues (SITSA) Act of 2017
S.1553-Stopping Overdoses of Fentanyl Analogues Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Wooster |
|
Associate Executive Director, Public Affairs |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Ryan |
McBride |
|
Senior Congressional Lobbyist |
|
Jeanne |
Slade |
|
Director, NEMPAC & ACEP Grassroots Advocacy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Essential emergency medication shortages
H.R.2410-Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017
H.R.6615-Traumatic Brain Injury Program Reauthorization Act of 2018
H.R.6748-Emergency Medical Services for Children Program Reauthorization Act of 2018
H.R.7223-Right Rebate Act of 2018
S.2465-Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2018
S.3482-Emergency Medical Services for Children Program Reauthorization Act of 2018
S.3657-Traumatic Brain Injury Program Reauthorization Act of 2018
S.3702-Right Rebate Act of 2018
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Wooster |
|
Associate Executive Director, Public Affairs |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Ryan |
McBride |
|
Senior Congressional Lobbyist |
|
Jeanne |
Slade |
|
Director, NEMPAC & ACEP Grassroots Advocacy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R.817-End Surprise Billing Act of 2017
H.R.1323-Reducing Unnecessary Emergency Room Visits under Medicaid Act
H.R.2957-Save Rural Hospitals Act
H.R.3181-Medicare Choices Empowerment and Protection Act
H.R.5678-Rural Emergency Medical Center Act of 2018
H.R.6502-Reducing Unnecessary Senior Hospitalizations Act of 2018
H.R.7223-Right Rebate Act of 2018
S.260-Protecting Seniors' Access to Medicare Act of 2017
S.284-End Surprise Billing Act of 2017
S.568-Improving Access to Medicare Coverage Act of 2017
S.1130-Rural Emergency Acute Care Hospital (REACH) Act
S.1530- Medicare Choices Empowerment and Protection Act
S.3531-Emergency Care Improvement Act
S.3702-Right Rebate Act of 2018
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Wooster |
|
Associate Executive Director, Public Affairs |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Ryan |
McBride |
|
Senior Congressional Lobbyist |
|
Jeanne |
Slade |
|
Director, NEMPAC & ACEP Grassroots Advocacy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
H.R.6143-Patient Right to Know Drug Prices Act
H.R.6144-Know the Lowest Price Act of 2018
H.R.6733-Know the Cost Act of 2018
H.R.7223-Right Rebate Act of 2018
S.2544-Patient Right to Know Drug Prices Act
S.2553-Know the Lowest Price Act of 2018
S.3702-Right Rebate Act of 2018
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Wooster |
|
Associate Executive Director, Public Affairs |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Ryan |
McBride |
|
Senior Congressional Lobbyist |
|
Jeanne |
Slade |
|
Director, NEMPAC & ACEP Grassroots Advocacy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SPO
16. Specific lobbying issues
H.R.1492-Medical Controlled Substances Transportation Act of 2017
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Wooster |
|
Associate Executive Director, Public Affairs |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Ryan |
McBride |
|
Senior Congressional Lobbyist |
|
Jeanne |
Slade |
|
Director, NEMPAC & ACEP Grassroots Advocacy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TEC
16. Specific lobbying issues
S.1016-Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2017
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Wooster |
|
Associate Executive Director, Public Affairs |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Ryan |
McBride |
|
Senior Congressional Lobbyist |
|
Jeanne |
Slade |
|
Director, NEMPAC & ACEP Grassroots Advocacy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOR
16. Specific lobbying issues
H.R.548-Health Care Safety Net Enhancement Act of 2017
H.R.720-Lawsuit Abuse Reduction Act
H.R.1215-Protecting Access to Care Act of 2017
H.R.1565-Saving Lives, Saving Costs Act
H.R.1822-Good Samaritan Health Professionals Act of 2017
H.R.1876-Good Samaritan Health Professionals Act of 2017
S.527-Health Care Safety Net Enhancement Act of 2017
S.781-Good Samaritan Health Professionals Act of 2017
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Wooster |
|
Associate Executive Director, Public Affairs |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Ryan |
McBride |
|
Senior Congressional Lobbyist |
|
Jeanne |
Slade |
|
Director, NEMPAC & ACEP Grassroots Advocacy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
Veterans Affairs Emergency Medicine Research, Education and Clinical Centers
17. House(s) of Congress and Federal agencies Check if None
Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Wooster |
|
Associate Executive Director, Public Affairs |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Ryan |
McBride |
|
Senior Congressional Lobbyist |
|
Jeanne |
Slade |
|
Director, NEMPAC & ACEP Grassroots Advocacy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |